These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 23408105

  • 1. Synergistic effect of the γ-secretase inhibitor PF-03084014 and docetaxel in breast cancer models.
    Zhang CC, Yan Z, Zong Q, Fang DD, Painter C, Zhang Q, Chen E, Lira ME, John-Baptiste A, Christensen JG.
    Stem Cells Transl Med; 2013 Mar; 2(3):233-42. PubMed ID: 23408105
    [Abstract] [Full Text] [Related]

  • 2. Notch Pathway Inhibition Using PF-03084014, a γ-Secretase Inhibitor (GSI), Enhances the Antitumor Effect of Docetaxel in Prostate Cancer.
    Cui D, Dai J, Keller JM, Mizokami A, Xia S, Keller ET.
    Clin Cancer Res; 2015 Oct 15; 21(20):4619-29. PubMed ID: 26202948
    [Abstract] [Full Text] [Related]

  • 3. Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models.
    Zhang CC, Pavlicek A, Zhang Q, Lira ME, Painter CL, Yan Z, Zheng X, Lee NV, Ozeck M, Qiu M, Zong Q, Lappin PB, Wong A, Rejto PA, Smeal T, Christensen JG.
    Clin Cancer Res; 2012 Sep 15; 18(18):5008-19. PubMed ID: 22806875
    [Abstract] [Full Text] [Related]

  • 4. HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro.
    Du Z, Li L, Sun W, Wang X, Zhang Y, Chen Z, Yuan M, Quan Z, Liu N, Hao Y, Li T, Wang J, Luo C, Wu X.
    Int J Oncol; 2018 Jul 15; 53(1):99-112. PubMed ID: 29658567
    [Abstract] [Full Text] [Related]

  • 5. Evaluation of selective gamma-secretase inhibitor PF-03084014 for its antitumor efficacy and gastrointestinal safety to guide optimal clinical trial design.
    Wei P, Walls M, Qiu M, Ding R, Denlinger RH, Wong A, Tsaparikos K, Jani JP, Hosea N, Sands M, Randolph S, Smeal T.
    Mol Cancer Ther; 2010 Jun 15; 9(6):1618-28. PubMed ID: 20530712
    [Abstract] [Full Text] [Related]

  • 6. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
    Yabuuchi S, Pai SG, Campbell NR, de Wilde RF, De Oliveira E, Korangath P, Streppel MM, Rasheed ZA, Hidalgo M, Maitra A, Rajeshkumar NV.
    Cancer Lett; 2013 Jul 10; 335(1):41-51. PubMed ID: 23402814
    [Abstract] [Full Text] [Related]

  • 7. Preclinical and clinical studies of gamma secretase inhibitors with docetaxel on human breast tumors.
    Schott AF, Landis MD, Dontu G, Griffith KA, Layman RM, Krop I, Paskett LA, Wong H, Dobrolecki LE, Lewis MT, Froehlich AM, Paranilam J, Hayes DF, Wicha MS, Chang JC.
    Clin Cancer Res; 2013 Mar 15; 19(6):1512-24. PubMed ID: 23340294
    [Abstract] [Full Text] [Related]

  • 8. PEST domain mutations in Notch receptors comprise an oncogenic driver segment in triple-negative breast cancer sensitive to a γ-secretase inhibitor.
    Wang K, Zhang Q, Li D, Ching K, Zhang C, Zheng X, Ozeck M, Shi S, Li X, Wang H, Rejto P, Christensen J, Olson P.
    Clin Cancer Res; 2015 Mar 15; 21(6):1487-96. PubMed ID: 25564152
    [Abstract] [Full Text] [Related]

  • 9. Nicastrin and Notch4 drive endocrine therapy resistance and epithelial to mesenchymal transition in MCF7 breast cancer cells.
    Lombardo Y, Faronato M, Filipovic A, Vircillo V, Magnani L, Coombes RC.
    Breast Cancer Res; 2014 Jun 11; 16(3):R62. PubMed ID: 24919951
    [Abstract] [Full Text] [Related]

  • 10. Phase I study of the gamma secretase inhibitor PF-03084014 in combination with docetaxel in patients with advanced triple-negative breast cancer.
    Locatelli MA, Aftimos P, Dees EC, LoRusso PM, Pegram MD, Awada A, Huang B, Cesari R, Jiang Y, Shaik MN, Kern KA, Curigliano G.
    Oncotarget; 2017 Jan 10; 8(2):2320-2328. PubMed ID: 27906684
    [Abstract] [Full Text] [Related]

  • 11. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts.
    Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N, Koh C, Zhang J, Li YM, Maciaczyk J, Nikkhah G, Dimeco F, Piccirillo S, Vescovi AL, Eberhart CG.
    Stem Cells; 2010 Jan 10; 28(1):5-16. PubMed ID: 19904829
    [Abstract] [Full Text] [Related]

  • 12. Ulinastatin exerts synergistic effects with taxotere and inhibits invasion and metastasis of breast cancer by blocking angiogenesis and the epithelial-mesenchymal transition.
    Gao F, Sun Z, Sun X, Zhang Y, Wang H, Zhong B, Luo J, Zhao X.
    Cancer Biother Radiopharm; 2013 Apr 10; 28(3):218-25. PubMed ID: 23477357
    [Abstract] [Full Text] [Related]

  • 13. Strong therapeutic potential of γ-secretase inhibitor MRK003 for CD44-high and CD133-low glioblastoma initiating cells.
    Tanaka S, Nakada M, Yamada D, Nakano I, Todo T, Ino Y, Hoshii T, Tadokoro Y, Ohta K, Ali MA, Hayashi Y, Hamada J, Hirao A.
    J Neurooncol; 2015 Jan 10; 121(2):239-50. PubMed ID: 25293440
    [Abstract] [Full Text] [Related]

  • 14. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
    Calcagno AM, Salcido CD, Gillet JP, Wu CP, Fostel JM, Mumau MD, Gottesman MM, Varticovski L, Ambudkar SV.
    J Natl Cancer Inst; 2010 Nov 03; 102(21):1637-52. PubMed ID: 20935265
    [Abstract] [Full Text] [Related]

  • 15. A novel triazole, NMK-T-057, induces autophagic cell death in breast cancer cells by inhibiting γ-secretase-mediated activation of Notch signaling.
    Das A, Narayanam MK, Paul S, Mukhnerjee P, Ghosh S, Dastidar DG, Chakrabarty S, Ganguli A, Basu B, Pal M, Chatterji U, Banerjee SK, Karmakar P, Kumar D, Chakrabarti G.
    J Biol Chem; 2019 Apr 26; 294(17):6733-6750. PubMed ID: 30824542
    [Abstract] [Full Text] [Related]

  • 16. PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts.
    Zhang C, Yan Z, Painter CL, Zhang Q, Chen E, Arango ME, Kuszpit K, Zasadny K, Hallin M, Hallin J, Wong A, Buckman D, Sun G, Qiu M, Anderes K, Christensen JG.
    Clin Cancer Res; 2009 Jul 15; 15(14):4630-40. PubMed ID: 19584159
    [Abstract] [Full Text] [Related]

  • 17. ALDH activity selectively defines an enhanced tumor-initiating cell population relative to CD133 expression in human pancreatic adenocarcinoma.
    Kim MP, Fleming JB, Wang H, Abbruzzese JL, Choi W, Kopetz S, McConkey DJ, Evans DB, Gallick GE.
    PLoS One; 2011 Jul 15; 6(6):e20636. PubMed ID: 21695188
    [Abstract] [Full Text] [Related]

  • 18. Preclinical analysis of the γ-secretase inhibitor PF-03084014 in combination with glucocorticoids in T-cell acute lymphoblastic leukemia.
    Samon JB, Castillo-Martin M, Hadler M, Ambesi-Impiobato A, Paietta E, Racevskis J, Wiernik PH, Rowe JM, Jakubczak J, Randolph S, Cordon-Cardo C, Ferrando AA.
    Mol Cancer Ther; 2012 Jul 15; 11(7):1565-75. PubMed ID: 22504949
    [Abstract] [Full Text] [Related]

  • 19. Combined Erlotinib and PF-03084014 treatment contributes to synthetic lethality in head and neck squamous cell carcinoma.
    Zheng Y, Wang Z, Ding X, Dong Y, Zhang W, Zhang W, Zhong Y, Gu W, Wu Y, Song X.
    Cell Prolif; 2018 Jun 15; 51(3):e12424. PubMed ID: 29232766
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.